Sprifermin is another name for human recombinant FGF18. Its manufacturers hope it will soon enter clinical trials for treatment of knee osteoarthritis.[1]


This article is issued from Wikipedia - version of the 6/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.